Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology And Recombinant Collagen III Platform; Co. To Pay FibroGen $8M Up Front And Up To $64M In Milestones As Well As $46M In Commercial Milestones
Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea
Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea
Biosynthetic